Ankylosing Spondylitis
Ancient skeleton with RA may suggest ‘we’ve been dealing with these diseases forever’
Archaeologists in Egypt recently discovered evidence of an ancient case of rheumatoid arthritis, potentially filling in the timeline of humanity’s relationship with autoimmune disease.
Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand
Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.
Rheumatologists influential in smoking cessation for patients with ankylosing spondylitis
A rheumatologist’s decision to ask about tobacco use may potentially be the leading factor in whether a patient with ankylosing spondylitis quits smoking, according to data published in Cureus.
FDA approves intravenous formulation of secukinumab
The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press release from Novartis.
FDA approves Abrilada as second interchangeable adalimumab biosimilar
The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.
Reported fracture rates in ankylosing spondylitis have more than doubled since 2000
The introduction of TNF inhibitors in 2003 has failed to stop fracture rates in patients with ankylosing spondylitis from more than doubling from 2000 to 2020, according to data published in Arthritis Care & Research.
FDA grants competitive generic therapy approval for indomethacin suppositories
The FDA has granted final approval to Zydus Lifesciences to manufacture and market generic indomethacin 50 mg suppositories, according to a company press release.
‘My life was falling apart’: Former NBA mascot recalls nurse’s empathy after AS diagnosis
AUSTIN, Texas — A former NBA mascot encouraged attendees of the 2023 Rheumatology Nurses Society annual conference to make the most of every moment they have with their patients, as their time and empathy can make all the difference.
Upadacitinib impactful vs placebo in psoriatic arthritis with axial involvement
Patients with psoriatic arthritis and axial involvement experienced greater improvement when treated with upadacitinib 15 mg compared with placebo and adalimumab, according to data published in Arthritis Research & Therapy.
Coherus to launch adalimumab biosimilar in US at 85% discount
Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.